Syros Pharmaceuticals, Inc. on September 28, 2023 announced that Mark J. Alles resigned from the Board of Directors and all committees or subcommittees thereof, effective September 30, 2023. On September 28, 2023, Nancy Simonian, M.D., the President of the Company, provided the Company with notice of her desire and intention to retire, and on October 2, 2023, the Company announced Dr. Simonian?s retirement effective as of December 1, 2023 (the ? Retirement Date?).

Dr. Simonian will remain a member of the Company?s Board of Directors following the Retirement Date. On October 2, 2023, the Company also announced that Conley Chee, currently the Company?s Chief Commercial Officer and Chief Business Officer, has been appointed by the Board of Directors to serve as the Company?s President effective as of December 2, 2023. Effective upon his assumption of the role of President and Chief Executive Officer, Mr. Chee will replace Dr. Simonian as the Company?s principal executive officer.

The appointment of Mr. Chee was made pursuant to a succession plan developed and approved by the Board of Directors. The Board of Directors also approved an increase in the size of the Board of Directors to ten members and the appointment of Mr. Chee as a Class III director, in each case effective upon Mr. Chee?s assumption of the role of President and Chief Executive Officer. The Board of Directors believes Mr. Chee is qualified to serve as a member.

On October 2, 2023, the Company announced that Eric R. Olson, Ph.D., will depart from his position as Chief Scientific Officer, effective October 16, 2023.